Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

Discover a study that suggests that rencofilstat 225mg/d improves both liver function and portal-systemic shunting.

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

32.7% (p=0.004 vs placebo) of F3-F4 patients treated with 600 mg icosabutate achieved ≥1-stage improvement in fibrosis without worsening of MASH versus 9.6% of placebo treated patients as ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.